Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval

Related Articles

Fiserv Stock Slumps as CFO Says Clover Growth Will Likely Remain Flat

High Tariffs Could Pinch Profits at Walmart, Retailer Says

Delta Air Lines Is Rebranding Its Ticket Tiers. Here’s Why.

Key Takeaways

• Vertex Pharmaceuticals’ non-opioid painkiller received approval from the Food and Drug Administration.
• The drugmaker told the twice-daily pill, Journavx, is the first such treatment to hit the market in 20 years.
• Vertex set the U.S. wholesale price of Journavx at $15.50 per 50mg crank.

Shares of Vertex Pharmaceuticals (VRTX) surged Friday, a day after the drugmaker reported federal regulators have approved its non-opioid anaesthetic, the first such drug to head to market in two decades.

The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily lozenge that it described as a “highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe keen pain.”

CEO Dr. Reshma Kewalramani said Journavx was “the first new class of pain medicine approved in more than 20 years,” continuing that the treatment provides “the opportunity to change the paradigm of acute pain management and establish a new standard of care.”

Dr. Jessica Oswald, a fellow of the Vertex Acute Pain Steering Committee, called the approval “an incredible day for patients and physicians alike,” noting that Journavx can require pain relief and a safety profile “without addictive potential.”

Vertex explained that the wholesale purchase cost for Journavx in the U.S. would be $15.50 per 50mg pill. 

The news sent Vertex Pharmaceuticals shares, which had been up just 1% across the past 12 months, nearly 7% higher Friday morning.